← Oncology Approval Tracker

FDA DECISION ·

Keytruda + Lenvima

pembrolizumab with lenvatinib · Merck / Eisai

Traditional approvalTraditional conversionEndometrial cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Patients with advanced endometrial cancer that is neither MSI-high nor dMMR, with progression after systemic therapy and no option for curative surgery or radiation.

LAMPGEN ANALYSIS

Why it matters

This converts the earlier accelerated approval of the combination for biomarker-defined advanced endometrial cancer.

What research teams should watch

Verify MSI/MMR classification, systemic treatment history and why curative local treatment is unavailable.

PRIMARY RECORDS

Sources